Skip to Content

Theme 1: Innate immunity and signaling mechanisms

Overview:  One reason why many current forms of cancer immunotherapy have low clinical response rates is because they fail to activate the innate immune system - a prerequisite for forming long-lasting adaptive immune responses that are necessary to eliminate tumors and prevent their recurrence.  Hence, several CCIR members are investigating the biology of innate immune cells and innate receptor-mediated signal transduction pathways leading to the expression of cytokines and costimulatory molecules involved in T cell activation and differentiation in order to find ways to enable cancer immunotherapy to activate innate immunity and result in the generation of durable anti-tumor T cell responses.  

Relevant Publications (most recent - 2008):


© 2013 The University of Texas MD Anderson Cancer Center